Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1753–1776 of 5,569 matching trials from the live ClinicalTrials.gov search.
Conditions
Alzheimer's Disease
Interventions
Psilocybin, Cognitive Training
Drug · Other
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
65 Years to 120 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Early Alzheimer's Disease
Interventions
E2609
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Conditions
Dementia
Interventions
Health System-based Dementia Care, Community-based Dementia Care, Usual Care
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
2,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Winston-Salem, North Carolina • Wilkes-Barre, Pennsylvania • Galveston, Texas + 1 more
Conditions
Degenerative Spinal Cord Disease
Interventions
Therapist-Guided Rehabilitation, Self-Guided Rehabilitation
Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Evanston, Illinois
Completed No phase listed Observational Accepts healthy volunteers

Instrumented Data Exchange for Ataxia Study

NCT04268147
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
12 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
[123I]B-CIT
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
21 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Movement Disorders, Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
General Anesthesia
Interventions
Propofol, Isoflurane
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Motor Neuron Disease
Interventions
FLX-787-ODT (orally disintegrating tablet), Placebo ODT
Drug
Lead sponsor
Flex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
35
States / cities
Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
Completed No phase listed Observational

Florbetaben PET Imaging in PPA

NCT04720001
Conditions
Primary Progressive Aphasia, Alzheimer Disease
Interventions
Florbetaben F18, PET
Drug · Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 100 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Tic Disorders, Tics, Tic, Motor, Tic Disorder, Childhood, Tourette Syndrome, Tourette Syndrome in Children, Tourette Syndrome in Adolescence
Interventions
Comprehensive Behavioral Intervention for Tics (CBIT), Repetitive Transcranial Magnetic Stimulation (rTMS), Continuous Theta Burst Stimulation (cTBS)
Behavioral · Device
Lead sponsor
University of Minnesota
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
SNUG01
Drug
Lead sponsor
SineuGene Therapeutics Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Canavan Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 99 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts • New York, New York
Conditions
Pantothenate Kinase-Associated Neurodegeneration
Interventions
Fosmetpantotenate, Placebo
Drug
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
6 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
9
States / cities
Irvine, California • Washington D.C., District of Columbia • Miami, Florida + 6 more
Conditions
Down Syndrome, Down Syndrome, Partial Trisomy 21, Alzheimer Disease
Interventions
[18F]-FEOBV Radiotracer
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Overactive Bladder
Interventions
onaBoNT-A, Oxybutynin ER
Drug
Lead sponsor
Christopher Patrick Smith
Other
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Houston, Texas
Conditions
Cerebral Palsy, Arthrogryposis, Spinal Muscular Atrophy, Other Central Nervous System or Musculoskeletal Disorders
Interventions
Power mobility
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
14 Months to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Hereditary Ataxia
Interventions
Not listed
Lead sponsor
Office of Rare Diseases (ORD)
NIH
Eligibility
3 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
Galveston, Texas
Conditions
Chronic Dysphagia, Multiple Sclerosis, Parkinson Disease
Interventions
Neurostimulation device for dysphagia, External vibrotactile device
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Regimen I NUZ-001

NCT07410806
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
NUZ-001, Matching placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson's Disease
Interventions
CVT-301, Sinemet
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
30 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
5
States / cities
Long Beach, California • Hallandale, Florida • Orlando, Florida + 2 more
Conditions
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 110 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland